Treatment of cytomegalovirus ketinitis with a sustained-release ganciclovir implant

New England Journal of Medicine

Volumn 337, Issue 2, 1997, Pages 83-90

  Musch, David C ^a   Martin, Daniel F ^b   Gordon, Judy F ^c   Davis, Matthew D ^d   Kuppermann, Baruch D ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; ANTIVIRUS AGENT;

ADULT; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; INTRAOCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; SUSTAINED RELEASE PREPARATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPARATIVE STUDY; DISEASE COURSE; DRUG IMPLANT; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; DISEASE PROGRESSION; DRUG IMPLANTS; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031563023     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199707103370203     Document Type: Article

References (61)

1. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983;90:859-73.
2. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984;97:133-42.
3. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984;91: 1092-9.
4. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;5: 1069-74.
5. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
6. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115: 575-82.
7. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985;92:472-84.
8. Henderly DE, Freeman WR, Smith RE, Causey D, Rao NA. Cytomegalovirus retinitis as the initial manifestation of the acquired immune deficiency syndrome. Am J Ophthalmol 1987;103:316-20.
9. Palestine AG, Steven G Jr, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol 1986;101:95-101.
10. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;341:801-5.
11. Holland GN, Sakamoto MJ, Hardy D, Sidikaro Y, Kreiger AE, Frenkel LM. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome: use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch Ophthalmol 1986;104: 1794-800.
12. Henderly DE, Freeman WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987;94: 425-34.
13. Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987;94:815-23.
14. Jabs DA, Newman C, DeBustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30.
15. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
16. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990;97:681-6.
17. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
18. Walmsley SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988;157:569-72.
19. Lehoang P, Girard B, Robinet M, et al. Foscarnet in-the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989;96:865-74.
20. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retiniris in AIDS. J Acquir Immune Defic Syndr 1990;3:472-9.
21. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33:736-41.
22. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61.
23. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med 1997;126:257-63.
24. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial: a randomized, controlled trial. Ann Intern Med 1997;126: 264-74.
25. Idem. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20. [Erratum, N Engl J Med 1992; 326:1172.]
26. Idem. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65-74.
27. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease combined with AIDS. Ann Intern Med 1990;113:111-7.
28. Studies of the Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Rctreatment Trial. Arch Ophthalmol 1996;114:23-33.
29. Henry K, Cantrill HL, Fletcher C, Chinnock BJ, Balfour HH Jr. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23.
30. Ussery FM III, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988;95:640-8.
31. Cantrill HL, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH Jr. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989;96:367-74.
32. Heinemann M-H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinotherapy. Arch Ophthalmol 1989;107:1767-72.
33. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-53.
34. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992;110:255-8.
35. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992;110:188-95.
36. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993;111:223-7.
37. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
38. Ganciclovir intraocular device and patient survival. Arch Ophthalmol 1994;112:19-20.
39. Morlet N, Young SH, Coroneo MT. Ganciclovir intraocular device and patient survival. Arch Ophthalmol 1994;112:1404.
40. Polis MA, Masur H. Promising new treatments for cytomegalovirus retinitis. JAMA 1995;273:1457-9.
41. Engstrom RE Jr, Holland GN. Local therapy for cytomegalovirus retinopathy. Am J Ophthalmol 1995;120:376-85.
42. Irvine AR. Intraocular sustained drug release devices. Arch Ophthalmol 1995;113:25-6.
43. Friedberg DN. Treatment of cytomegalovirus retinitis with intraocular sustained release ganciclovir implant. Arch Ophthalmol 1995;113:1354-5.
44. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6.
45. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
46. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
47. Therneau TM. Extending the Cox model. Technical report no. 58. Rochester, Minn.: Department of Health Science Research, Mayo Foundation, June 1996.
48. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993; 168:1506-9.
49. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:951-6.
50. Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983;24:518-21.
51. Plotkin SA, Drew WL, Felsentein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;152:833-4.
52. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
53. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993;116:713-20.
54. Sandy CJ, Bloom PA, Graham EM, et al. Retinal detachment in AIDS-related cytomegalovirus retinitis. Eye 1995;9:277-81.
55. Freeman WR, Hendcrly DE, Wan WL, et al. Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis. Am J Ophthalmol 1987;103:527-36.
56. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
57. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990;97:681-6.
58. Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991;109:794-9.
59. Orellana J, Teich SA, Leiberman RM, Restrepo S, Peairs R. Treatment of retinal detachments in patients with the acquired immune deficiency syndrome. Ophthalmology 1991;98:939-43.
60. Sidikaro Y, Silver L, Holland GN, Kreiger AE. Rhegmatogenous retinal detachments in patients with AIDS and necrotizing retinal infections. Ophthalmology 1991;98:129-35.
61. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.